Literature DB >> 22109562

The effect of JDP2 and ATF2 on the epithelial-mesenchymal transition of human pancreatic cancer cell lines.

Yuanhong Xu1, Zhe Liu, Kejian Guo.   

Abstract

Pancreatic cancer is a common malignancy with a bleak outcome due to the early occurrence of micro-metastases and poor prognosis. The epithelial-mesenchymal transition (EMT) is considered to be related to the invasion and metastasis of a variety of malignant tumors. Currently, there is no research regarding the relationship of pancreatic cancer EMT with Jun dimerization protein 2 (JDP2), an inhibitor of the activator protein-1 (AP-1) family, and activating transcription factor-2 (ATF2), an AP-1-family member. In this study, we used western blot analysis and immunofluorescence to detect the protein expression of the epithelial marker E-cadherin and the mesenchymal marker vimentin in the pancreatic cancer cell line BxPC3, which was transfected with JDP2 and induced by Collagen I. Compared with the negative control, the E-cadherin and vimentin expression levels did not change significantly, whereas E-cadherin expression decreased and vimentin expression increased in the control group transfected with empty plasmid, suggesting that JDP2 inhibits the EMT induced by Collagen I. Additionally, we verified that compared with the negative control, the morphology of the Capan2 cell line induced by TGF-β1 after transfection with ATF2 was significantly changed, as was the mRNA expression of E-cadherin, whereas the mRNA expression of vimentin, Snail, and ATF2 was significantly increased. Cell invasiveness was also significantly increased (P < 0.01), suggesting that ATF2, together with TGF-β1, induced EMT in the Capan2 cell line. The members of the AP-1 family are closely related to EMT and that JDP2, as an AP-1-family inhibitor, inhibits EMT, which could lead to a new direction in molecular-targeted therapy for pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22109562     DOI: 10.1007/s12253-011-9476-6

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  28 in total

1.  Epithelial mesenchymal transition and lung cancer.

Authors:  Dakai Xiao; Jianxing He
Journal:  J Thorac Dis       Date:  2010-09       Impact factor: 2.895

2.  Emerging therapies in pancreas cancer.

Authors:  Adam Kotowski; Wen W Ma
Journal:  J Gastrointest Oncol       Date:  2011-06

3.  Isolation of an AP-1 repressor by a novel method for detecting protein-protein interactions.

Authors:  A Aronheim; E Zandi; H Hennemann; S J Elledge; M Karin
Journal:  Mol Cell Biol       Date:  1997-06       Impact factor: 4.272

4.  Heterodimer formation between CREB and JUN proteins.

Authors:  D M Benbrook; N C Jones
Journal:  Oncogene       Date:  1990-03       Impact factor: 9.867

5.  Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival.

Authors:  Aaron J Berger; Harriet M Kluger; Ning Li; Eric Kielhorn; Ruth Halaban; Ze'ev Ronai; David L Rimm
Journal:  Cancer Res       Date:  2003-12-01       Impact factor: 12.701

Review 6.  Molecular pathology of pancreatic cancer: implications for molecular targeting therapy.

Authors:  Toru Furukawa
Journal:  Clin Gastroenterol Hepatol       Date:  2009-11       Impact factor: 11.382

7.  Crystal structure of the heterodimeric bZIP transcription factor c-Fos-c-Jun bound to DNA.

Authors:  J N Glover; S C Harrison
Journal:  Nature       Date:  1995-01-19       Impact factor: 49.962

8.  Activating transcription factor 2 (ATF2) controls tolfenamic acid-induced ATF3 expression via MAP kinase pathways.

Authors:  S-H Lee; J H Bahn; N C Whitlock; S J Baek
Journal:  Oncogene       Date:  2010-06-28       Impact factor: 9.867

9.  Downregulation of AP-1 repressor JDP2 is associated with tumor metastasis and poor prognosis in patients with pancreatic carcinoma.

Authors:  Xu Yuanhong; Xu Feng; Li Qingchang; Fan Jianpeng; Liu Zhe; Guo Kejian
Journal:  Int J Biol Markers       Date:  2010 Jul-Sep       Impact factor: 3.248

10.  p38 mitogen-activated protein kinase is required for TGFbeta-mediated fibroblastic transdifferentiation and cell migration.

Authors:  Andrei V Bakin; Cammie Rinehart; Anne K Tomlinson; Carlos L Arteaga
Journal:  J Cell Sci       Date:  2002-08-01       Impact factor: 5.285

View more
  6 in total

1.  miR-501 acts as an independent prognostic factor that promotes the epithelial-mesenchymal transition through targeting JDP2 in hepatocellular carcinoma.

Authors:  Weixuan Yu; Wen Deng; Qiang Zhao; Hongkai Zhuang; Chuanzhao Zhang; Zhixiang Jian
Journal:  Hum Cell       Date:  2019-03-15       Impact factor: 4.174

2.  Expression profiling of cervical cancers in Indian women at different stages to identify gene signatures during progression of the disease.

Authors:  Asha Thomas; Umesh Mahantshetty; Sadhana Kannan; Kedar Deodhar; Shyam K Shrivastava; Chandan Kumar-Sinha; Rita Mulherkar
Journal:  Cancer Med       Date:  2013-10-31       Impact factor: 4.452

3.  GLUT3 Promotes Epithelial-Mesenchymal Transition via TGF-β/JNK/ATF2 Signaling Pathway in Colorectal Cancer Cells.

Authors:  Moon-Young Song; Da-Young Lee; Sun-Mi Yun; Eun-Hee Kim
Journal:  Biomedicines       Date:  2022-07-29

4.  ATF2 predicts poor prognosis and promotes malignant phenotypes in renal cell carcinoma.

Authors:  Deng-Shuang Wu; Cheng Chen; Zhen-Jie Wu; Bing Liu; Li Gao; Qing Yang; Wei Chen; Jun-Ming Chen; Yi Bao; Le Qu; Lin-Hui Wang
Journal:  J Exp Clin Cancer Res       Date:  2016-07-04

5.  Identification of four differentially methylated genes as prognostic signatures for stage I lung adenocarcinoma.

Authors:  Wei-Ming Luo; Zheng-Yu Wang; Xin Zhang
Journal:  Cancer Cell Int       Date:  2018-04-19       Impact factor: 5.722

Review 6.  The activating transcription factor 2: an influencer of cancer progression.

Authors:  Kerstin Huebner; Jan Procházka; Ana C Monteiro; Vijayalakshmi Mahadevan; Regine Schneider-Stock
Journal:  Mutagenesis       Date:  2019-12-19       Impact factor: 3.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.